The Reality of BPH Surgery Price and Reimbursement Across Top U.S. Hospitals

INTRODUCTION AND OBJECTIVES: A growing number of surgical treatments are available for benign prostatic hyperplasia (BPH), each with distinct clinical profiles and resource demands. Wide variations in cost and reimbursement are understood to exist due to hospital-insurer negotiations, but are rarely quantified. The 2021 Medicare Price Transparency Final Rule now provides publicly available pricing data, allowing objective evaluation of real-world costs. We used these data to assess hospital charges and commercial reimbursement for common BPH procedures. METHODS: Charges and commercial reimbursement were obtained from the Turquoise Health database, which compiles pricing reported under Medicare transparency regulations. We analyzed procedure type, hospital, payer class, and service location among US News Top 20 hospitals. RESULTS: Charges varied by procedure, highest median charge associated with transurethral waterjet ablation [$15,742 ($11,281-$27,707)] and lowest for prostatic urethral lift [$4,489 ($1,228-$46,289)]. Private insurers were associated with higher charges. Significant inter-hospital variation was observed for prostatic urethral lift (p<0.001) and transurethral waterjet ablation (p<0.05). On multivariate analysis, hospital and payer predicted charges, while procedure type did not. Reimbursement also varied, highest median reimbursement was associated with transurethral waterjet ablation [$12,476.49 ($8938.33- $29,208.64] and lowest for transurethral resection of the prostate [$4,258.94 ($2,889.88-$40,949.00). Variation was driven by procedure type and care setting, but not institution. CONCLUSIONS: Substantial variation in BPH procedure pricing and reimbursement persists across top-ranked hospitals despite Medicare's price transparency regulations. Price variation appears more influenced by non-procedural factors, highlighting inequities in institutional negotiations and the need for further evaluation of hospital pricing patterns.

Authors

Institutions

Publication Details

Journal
Urology Practice
Published
2026-06-09
DOI
https://doi.org/10.1097/upj.0000000000001033
Primary Topic
Urinary Bladder and Prostate Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Reality of BPH Surgery Price and Reimbursement Across Top U.S. Hospitals

Dan Kelleher, Kevin Wymer, Gillian Murray, Victoria Edmonds et al.
Urology Practice
Urinary Bladder and Prostate Research
article

The Reality of BPH Surgery Price and Reimbursement Across Top U.S. Hospitals

Dan Kelleher, Kevin Wymer, Gillian Murray, Victoria Edmonds, Bijan Borah
article en

Abstract

INTRODUCTION AND OBJECTIVES: A growing number of surgical treatments are available for benign prostatic hyperplasia (BPH), each with distinct clinical profiles and resource demands. Wide variations in cost and reimbursement are understood to exist due to hospital-insurer negotiations, but are rarely quantified. The 2021 Medicare Price Transparency Final Rule now provides publicly available pricing data, allowing objective evaluation of real-world costs. We used these data to assess hospital charges and commercial reimbursement for common BPH procedures. METHODS: Charges and commercial reimbursement were obtained from the Turquoise Health database, which compiles pricing reported under Medicare transparency regulations. We analyzed procedure type, hospital, payer class, and service location among US News Top 20 hospitals. RESULTS: Charges varied by procedure, highest median charge associated with transurethral waterjet ablation [$15,742 ($11,281-$27,707)] and lowest for prostatic urethral lift [$4,489 ($1,228-$46,289)]. Private insurers were associated with higher charges. Significant inter-hospital variation was observed for prostatic urethral lift (p<0.001) and transurethral waterjet ablation (p<0.05). On multivariate analysis, hospital and payer predicted charges, while procedure type did not. Reimbursement also varied, highest median reimbursement was associated with transurethral waterjet ablation [$12,476.49 ($8938.33- $29,208.64] and lowest for transurethral resection of the prostate [$4,258.94 ($2,889.88-$40,949.00). Variation was driven by procedure type and care setting, but not institution. CONCLUSIONS: Substantial variation in BPH procedure pricing and reimbursement persists across top-ranked hospitals despite Medicare's price transparency regulations. Price variation appears more influenced by non-procedural factors, highlighting inequities in institutional negotiations and the need for further evaluation of hospital pricing patterns.

Urology Practice
Mayo Clinic (US), Mayo Clinic in Arizona (US), Mayo Clinic Hospital (US), Mayo Clinic in Florida (US)
Openalex Percentile: Top 6%
Urinary Bladder and Prostate Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.